What is LTRN's 12-month stock price target?

Lantern Pharma Inc. (LTRN) carries a 12-month consensus base price target of $0.56 (-12.5% from $0.64), with a bull-case target of $4.56 and a bear-case floor of $0.44.

Stock Ratings / Health Care / LTRN / forecast

BLRX (46) TPST (34) CALC (38) PHIO (37) ⌘ Pro Terminal →

Lantern Pharma Inc. (LTRN) 12-Month Stock Forecast & Price Target Cone

Q: Is LTRN stock a Buy, Hold, or Sell right now?

Roarable's 5-Pillar RQD Quant Engine rates LTRN E (Strong Sell — SELL) with an RQD Confidence score of 31/100.

$0.64 -3.15% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $0.64

Lantern Pharma Inc. (LTRN) carries a Roarable Rating of E (Strong Sell) with 31/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE E • RED ALERT Cap $9.9M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on LTRN Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is LTRN stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-03, Lantern Pharma Inc. (NASDAQ: LTRN) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 31/100 at a spot price of $0.64 (-3.15% 1D, market cap $9.9M). Pillar breakdown: Fundamental Cash Engine 6/20, Institutional 13F & Options Flow 3/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 7/20, and Executive Insider Alignment 5/20. Across 1015 tracked Health Care issuers, LTRN ranks #776 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does LTRN compare to BLRX and TPST in the Health Care sector?

▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), LTRN carries a Roarable E (31/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, BLRX (BioLineRx Ltd.) holds a D grade (46/100 RQD, P/E N/A, ROIC —, cap $9.9M) and TPST (Tempest Therapeutics Inc.) posts a E grade (34/100 RQD, P/E N/A, ROIC -35.0%, cap $9.9M). Among the 5-stock peer group, LTRN leads on earnings multiple (N/A) while LTRN leads on capital efficiency (-35.0% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for LTRN?

▼

Per LTRN's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001763950), Lantern Pharma Inc. generated $50.3M in revenue (-19.1% YoY), -$17.1M in net income, and -$15.7M in free cash flow against $11.0M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $0.64 (-0.76%)🧬 Disciplined Float (+0.72% YoY Shares)⚙️ Cash Engine: 6/20 (E) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (31/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-9.4% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERRED ALERT • E

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk D-

Each axis scored 0–20

12M PRICE TARGET CONE-12.5% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for LTRN)Realized 20D OHLCV Swing Band: ±12.5%

Deterministic 5-Pillar Attribution (31/100 Composite)

🔍 WHY LTRN SCORES 31/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: SEC 10-K Forensic Risk+10/20 pts (32% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 3/9

▲ #2 Bullish Driver: Macro Regime Fit+7/20 pts (23% of score)

FRED Regime × Technicals: 2% of 52W Range • RSI-14 at 34.5 (NEUTRAL RANGE)

▼ #1 Drag / Risk Factor: Whale & Options Positioning4/20 pts (-16 pt drag)

Put hedging (50% put share) caps near-term gamma upside (-16 pts vs max)

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade E$0.71-7% Next Q

Q2 (-2Q)

Grade E$0.66-3% Next Q

Q3 (-1Q)

Grade E$0.64+0% Next Q

Current

Grade E$0.64-9.4% Hist 90D α

Trajectory: E (39) → E (31)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a LTRN Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While LTRN currently carries a cautious 31/100 (E) rating due to Whale & Options Positioning (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($1.23) and Max Pain ($0.67) forces dealer call-delta covering toward $4.56.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.72% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $LTRN• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “LTRN Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 31%NO 69%Trade / Inspect Odds →

INTERACTIVE 12-MONTH POSITION SIMULATOR

Drag to Test Your LTRN Position Size: $10,000

Shares at $0.64: 15625.0 sh

$1,000$10,000$25,000$50,000$100,000

12M Bear Case FloorTarget $0.44

$6,875

$-3,125 (-31.3%)

12M Consensus BaseTarget $0.56

$8,750

$-1,250 (-12.5%)

12M Bull Case BreakoutTarget $4.56

$71,250

+$61,250 (+612.5%)

Wall Street Analyst Breakdown & Historical Accuracy Audit (35 Desks)

Street Historical Accuracy: 64/100

● Strong Buy / Buy: 17● Hold: 9● Sell: 9

Wall Street Firm	Stance	12M Target	1Y Accuracy	Track Grade
Morgan StanleyInstitutional Equity Desk	HOLD	$1	74%	A
Goldman SachsSector Coverage Lead	UNDERPERFORM	$4	69%	B
JP MorganUS Large-Cap Research	SELL	$1	58%	C

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring LTRN)

✓Walkthrough of LTRN's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

LTRN // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -71.30%⚡ TESTING RESISTANCE

2026-11-03O $0.73H $0.73L $0.64C $0.64VOL 218.5K

RES: $0.71SUP: $0.50SMA50: $1.23SMA200: $2.44

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

LTRN Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 LTRN Butterfly Map → + Track LTRN →

Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle

8.0%/yr Implied 5Y Growth

vs. -19.1% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on LTRN today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for LTRN. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for LTRN today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (LTRN)

Health Care Rank #776 of 1015 ⚔️ BLRX vs LTRN Full Matrix →

1. Head-to-Head Health Care Peer Comparison (LTRN vs. BLRX, TPST, CALC, PHIO)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, Lantern Pharma Inc. (LTRN) ranks #776 by composite RQD confidence (31/100, grade E) and #894 by equity capitalization ($9.9M). Within this direct 5-issuer industry benchmark cohort, LTRN leads on earnings valuation at N/A trailing P/E, while LTRN leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. BLRX currently holds the highest overall quantitative score in the immediate peer group at 46/100 (D) compared with LTRN at 31/100 (E).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
LTRN ACTIVE Lantern Pharma Inc.	E	31/100	—	—	-35.0%	-3.15%	$9.9M	Benchmark Subject
BLRX BioLineRx Ltd.	D	46/100	—	—	—	-1.51%	$9.9M	/blrx-vs-ltrn →
TPST Tempest Therapeutics Inc.	E	34/100	—	—	-35.0%	-4.74%	$9.9M	/tpst-vs-ltrn →
CALC CalciMedica Inc.	D-	38/100	—	—	-35.0%	-4.11%	$10.0M	/calc-vs-ltrn →
PHIO Phio Pharmaceuticals Corp.	D-	37/100	—	—	-35.0%	+2.33%	$10.0M	/phio-vs-ltrn →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001763950 ↗

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Lantern Pharma Inc. (LTRN) reported GAAP revenue of $50.3M (-19.1% vs. FY2024 revenue of $62.2M , and +0.6% cumulative change since FY2023) , GAAP net income of -$17.1M, operating cash flow of -$15.7M, and free cash flow of -$15.7M (+12.0% YoY). On the balance sheet, LTRN closed FY2025 with $11.0M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 3/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$50.3M	-$17.1M	-$15.7M	-$15.7M	$11.0M	—
FY2024 (FY)	2024-12-31	$62.2M	-$20.8M	-$17.8M	-$17.8M	$25.6M	—
FY2023 (FY)	2023-12-31	$50.1M	-$16.0M	-$14.3M	-$14.3M	—	—

3. LTRN Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is LTRN stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does LTRN compare to BLRX and TPST in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for LTRN?

Where is LTRN trading relative to its 50-day, 200-day, and 52-week technical levels?

LTRN last traded at $0.64 (-3.15% on volume of 176,075 shares), positioning the stock -47.97% below its 50-day simple moving average ($1.23) and -73.77% below its 200-day simple moving average ($2.44). Across its 52-week range of $0.59 to $4.34, LTRN sits at the 1.3% percentile with a 14-day RSI of 34.5 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($1.00 to $0.72).

Direct Sub-Reports: LTRN RQD Cockpit LTRN 12M Forecast LTRN Earnings & Move LTRN Dividends & DRIP LTRN Insiders & 13F LTRN Whale Options LTRN Profit Sankey LTRN News & Why

ROARABLE RATING BRIEF • RQD 31/100 (E) ✓ SEC XBRL & RQD VERIFIED

LTRN — Lantern Pharma Inc.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit

Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

Lantern Pharma Inc. (LTRN) earns a live Roarable RQD composite score of 31/100, corresponding to a E letter grade (Roarable Strong Sell) at a spot price of $0.64 (-3.15% 1D, market capitalization $9.9M).

Fundamental Cash Engine (6/20): Anchored by return on invested capital (ROIC) of -35.0%, gross margin of —, operating margin of —, and free cash flow yield of —.
Whale 13F & Options Flow (3/20) + Insider Conviction (5/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
Macro Regime Fit (7/20) + Forensic Balance Sheet (10/20): Incorporates a 1.00x equity beta, Altman Z-Score of N/A, Piotroski F-Score of 3/9, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

Lantern Pharma Inc. Is listed on NASDAQ and classified in the Health Care sector, within the Biotechnology: Pharmaceutical Preparations industry..0B in the profile section and $10.9M in market data. Reported revenue across the financial periods is —.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Lantern Pharma Inc. (LTRN) reported $50.3M in annual revenue (up from $62.2M in FY2024, -19.1% YoY) and -$17.1M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($50.1M revenue, -$16.0M net income) through FY2025, LTRN scaled operating cash flow to -$15.7M and free cash flow to -$15.7M, backed by $11.0M in total assets against $0 in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

🐂 Primary Bull Case (E • RQD 31/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of — and institutional whale pillar of 3/20. With Fundamental Cash Engine at 6/20 and Institutional Whale Flow at 3/20, sustained execution supports upside toward the upper end of the $0.59 – $4.34 52-week range.
🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against — operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

Operating in Biotechnology: Pharmaceutical Preparations (Health Care), LTRN carries a macro regime beta of 1.00 and gross margin of —.

Key Question #1: Can LTRN sustain or expand its — operating margin and -35.0% ROIC against Biotechnology: Pharmaceutical Preparations peers over the next 4 quarters?
Key Question #2: Following FY2025 revenue of $50.3M and free cash flow of -$15.7M, how will capital allocation balance growth reinvestment against $0 in total debt?
Key Question #3: How sensitive is LTRN's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

LTRN Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Lantern Pharma Inc. (LTRN) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to LTRN Debate Forum (3) ↓

🟡 MARKET WIRE Moomoo • 22h ago

Lantern Pharma(LTRN) Stock Options Chain | Quotes & News

Moomoo report covering Lantern Pharma Inc. (LTRN) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE TradingView • 1d ago

Lantern Pharma Inc. Estimates – NASDAQ:LTRN

TradingView report covering Lantern Pharma Inc. (LTRN) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Stock Titan • 1d ago

A reported Lantern Pharma (LTRN) stake includes 212,554 shares issuable through warrants.

Stock Titan report covering Lantern Pharma Inc. (LTRN) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟢 CATALYST TradingView • 1d ago

Weekly Recap: MVLS Nasdaq noncompliance and $4M equity raise with warrants

TradingView report covering Lantern Pharma Inc. (LTRN) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE https://www.siam.in/ • 1d ago

Lantern Pharma (LTRN) Slips 2.05% to $0.81, Drifting Toward Key Support - Break of Structure

https://www.siam.in/ report covering Lantern Pharma Inc. (LTRN) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔴 RISK WATCH https://www.dars.gov.et/ • 1d ago

Lantern Pharma (LTRN) Drops 14% to $0.86, Testing Key Support Zone - Sweep Order Flow

https://www.dars.gov.et/ report covering Lantern Pharma Inc. (LTRN) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

LTRN Bull vs. Bear Conversation Board — What's Your Call at $0.64?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON LTRN 🐻 33% BEARISH CONVICTION

QU QuantViper RQD DEBATE OPENER • Systematic Momentum Desk 🐂 BULLISH 🎯 Target: $0.82 (+24.2%)

📌 Pinned Debate

The stock trades near its 52-week low at $0.73 versus a $4.34 high, and a $4M equity raise with warrants is tagged as a catalyst.

Here is why I am bullish on LTRN here at $0.66: The stock trades near its 52-week low at $0.73 versus a $4.34 high, and a $4M equity raise with warrants is tagged as a catalyst.. Compare LTRN's 0.0% operating margin and -35.0% ROIC against the rest of Biotechnology: Pharmaceutical Preparations. As long as cash conversion holds up, dips toward $0.63 are getting bought.

RetailWhale_TX 🐂 BULL

@CreditSpread_Watch Shorting a 3/20 institutional whale-flow stock at $0.66 is dangerous when funds are rotating into Health Care.

CR CreditSpread_Watch RQD DEBATE OPENER • Balance Sheet Analyst 🐻 BEARISH 🎯 Target: $0.55 (-16.7%)

Spot @ $0.66

ROIC of -35%, FCF yield of 0%, and FY 2025 free cash flow of -$15.7M against $4.4M cash point to a forensic and cash-runway risk profil

Careful chasing LTRN at $0.66. ROIC of -35%, FCF yield of 0%, and FY 2025 free cash flow of -$15.7M against $4.4M cash point to a forensic and cash-runway risk profile.. Gross margin is 0.0%, but operating margin is 0.0%, which shows SG&A and reinvestment are eating into bottom-line EPS. Target $0.55 on multiple compression.